Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

21 Most research on GLP-1 agonists as a potential therapy for AUD focuses on the capacity of GLP-1s to modulate reward and pleasure-seeking mechanisms, much like they do in regulating food intake.